Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




    Laboratory findings in coronavirus disease MESHD 2019 (COVID-19) patients: a comprehensive systematic review and meta-analysis

    Authors: Mohammad Karimian; Amirreza Jamshidbeigi; Gholamreza Badfar; Milad Azami

    doi:10.1101/2020.06.07.20124602 Date: 2020-06-08 Source: medRxiv

    Background: In early December 2019, the first patient with COVID-19 pneumonia MESHD pneumonia HP was found in Wuhan, Hubei Province, China. Recent studies have suggested the role of primary laboratory tests in addition to clinical symptoms for suspected patients, which play a significant role in the diagnosis of COVID-19. Therefore, the present study was conducted to evaluate laboratory findings in COVID-19 patients. Material and methods: The present meta-analysis was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. This protocol is registered with the code CRD42019145410 in PROSPERO International Database. Results: Finally, 52 studies involving 5490 patients with COVID-19 entered the meta-analysis process. The prevalence SERO of leukopenia MESHD leukopenia HP, lymphopenia MESHD lymphopenia HP, elevated c-reactive protein (CRP), elevated erythrocyte sedimentation rate HP (ESR), elevated serum SERO amyloid A, elevated ferritin was estimated to be 20.9% (95%CI: 17.9-24.3), 51.6% (95%CI: 44.0-59.1), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 74.7% (95%CI: 50.0-89.7), and 72.6% (95%CI: 58.1-83.5), respectively. The prevalence SERO of elevated interleukin-6 was 59.9% (95%CI: 48.2-70.5), CD3 was 68.3% (95%CI: 50.1-82.2), reduced CD4 was 62.0% (95%CI: 51.1-71.6), reduced CD8 was 42.7% (95%CI: 32.2-53.9). The prevalence SERO of elevated troponin-I was 20.6% (95%CI: 9.0-40.5), elevated creatine kinase-MB (CKMB) was 14.7% (95%CI: 7.1-28.0), elevated brain natriuretic peptide (BNP) was 48.9% (95%CI: 30.4-67.7), elevated blood SERO urea nitrogen was 13.1% (95%CI: 6.6-24.4),, elevated creatinine was 7.2% (95%CI: 4.4-11.8), elevated lactate dehydrogenase (LDH) was 53.1% (95%CI: 43.6-62.4), hyperglycemia MESHD hyperglycemia HP was 41.1% (95% CI: 28.2-55.5), elevated total bilirubin was 48.9% (95%CI: 30.4-67.7), reduced albumin was 54.7% (95%CI: 38.1-70.2), reduced pre-albumin was 49.0% (95%CI: 26.6-71.8), and reduced PT was 53.1% (95% CI: 43.6-62.4), and D-dimer was 44.9% (95%CI: 31.0-59.6). Conclusion This study provides a comprehensive description of laboratory characteristics in patients with COVID-19. The results show that lymphopenia MESHD lymphopenia HP, elevated CRP, elevated ESR, elevated ferritin, elevated serum SERO amyloid A, elevated BNP, reduced albumin, reduced pre-albumin, reduced CD3, reduced CD4, reduced CD8, elevated D-dimer, reduced PT, elevated interleukin-2, elevated interleukin-6, elevated LDH and hyperglycemia MESHD hyperglycemia HP are the common findings at the time of admission.

    COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes

    Authors: Mohammad Ali Ashraf; Nasim Shokouhi; Elham Shirali; Fateme Davari-tanha; Omeed Memar; Alireza Kamalipour; Ayein Azarnoush; Avin Mabadi; Adele Ossareh; Milad Sanginabadi; Talat Mokhtari Azad; Leila Aghaghazvini; Sara Ghaderkhani; Tahereh Poordast; Alieh Pourdast; Pershang Nazemi

    doi:10.21203/rs.3.rs-26339/v1 Date: 2020-05-01 Source: ResearchSquare

    Background There is a growing need for information regarding the recent coronavirus disease MESHD of 2019 (Covid-19). We present a comprehensive report of Covid-19 patients in Iran.Methods One hundred hospitalized patients with Covid-19 were studied. Data on potential source of exposure, demographic, clinical, and paraclinical features, therapy outcome, and post-discharge follow-up were analyzed.Results The median age TRANS of the patients was 58 years, and the majority of the patients (72.7%) were above 50 years of age TRANS. Fever MESHD Fever HP was present in 45.2% of the patients on admission. The most common clinical symptoms were shortness of breath (74%) and cough MESHD cough HP (68%). Most patients had elevated C-reactive protein (92.3%), elevated erythrocyte sedimentation rate HP (82.9%), lymphocytopenia (74.2 %) on admission. Lower lobes of the lung were most commonly involved, and ground-glass opacity (81.8%) was the most frequent finding in CT scans. The administration of hydroxychloroquine improved the clinical outcome of the patients. Lopinavir/ritonavir was efficacious at younger ages TRANS. Of the 70 discharged patients, 40% had symptom relapse, (8.6%) were readmitted to the hospital, and 3 patients (4.3%) died.Conclusions  This report demonstrates a heterogeneous nature of clinical manifestations in patients affected with Covid-19. The most common presenting symptoms are non-specific, so attention should be made on broader testing, especially in age groups TRANS with the greatest risk and younger individuals who can serve as carriers TRANS of the disease MESHD. Hydroxychloroquine and lopinavir/ritonavir (in younger age group TRANS) can be potential treatment options. Finally, patients discharged from the hospital should be followed up because of potential symptom relapse.

    COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes

    Authors: Mohammad Ali Ashraf; Nasim Shokouhi; Elham Shirali; Fateme Davari-tanha; Omeed Memar; Alireza Kamalipour; Ayein Azarnoush; Avin Mabadi; Adele Ossareh; Milad Sanginabadi; Talat Mokhtari Azad; Leila Aghaghazvini; Sara Ghaderkhani; Tahereh Poordast; Alieh Pourdast; Pershang Nazemi

    doi:10.1101/2020.04.20.20072421 Date: 2020-04-24 Source: medRxiv

    Purpose There is a growing need for information regarding the recent coronavirus disease MESHD of 2019 (Covid-19). We present a comprehensive report of Covid-19 patients in Iran. Methods One hundred hospitalized patients with Covid-19 were studied. Data on potential source of exposure, demographic, clinical, and paraclinical features, therapy outcome, and post-discharge follow-up were analyzed. Results The median age TRANS of the patients was 58 years, and the majority of the patients (72.7%) were above 50 years of age TRANS. Fever MESHD Fever HP was present in 45.2% of the patients on admission. The most common clinical symptoms were shortness of breath (74%) and cough MESHD cough HP (68%). Most patients had elevated C-reactive protein (92.3%), elevated erythrocyte sedimentation rate HP (82.9%), lymphocytopenia (74.2 %) on admission. Lower lobes of the lung were most commonly involved, and ground-glass opacity (81.8%) was the most frequent finding in CT scans. The administration of hydroxychloroquine improved the clinical outcome of the patients. Lopinavir/ritonavir was efficacious at younger ages TRANS. Of the 70 discharged patients, 40% had symptom relapse, (8.6%) were readmitted to the hospital, and 3 patients (4.3%) died. Conclusion This report demonstrates a heterogeneous nature of clinical manifestations in patients affected with Covid-19. The most common presenting symptoms are non-specific, so attention should be made on broader testing, especially in age groups TRANS with the greatest risk and younger individuals who can serve as carriers TRANS of the disease MESHD. Hydroxychloroquine and lopinavir/ritonavir (in younger age group TRANS) can be potential treatment options. Finally, patients discharged from the hospital should be followed up because of potential symptom relapse.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.